Home / World / Pharma Firm in India to Make Russia’s Sputnik-V Covid-19 Vaccine
Pharma Firm in India to Make Russia's Sputnik-V Covid-19 Vaccine

Pharma Firm in India to Make Russia’s Sputnik-V Covid-19 Vaccine

MOSCOW – Indian pharmaceutical company Hetero will manufacture more than 100 million doses of Russia’s Sputnik V Covid-19 vaccine per year under a deal unveiled between Hetero and Russian sovereign wealth fund RDIF on Friday.
The move, which RDIF has touted as another step in its efforts to scale up international manufacture of its flagship vaccine, will see Hetero begin production in India early next year, according to a joint statement on Sputnik V’s Twitter account.
The statement said phase II-III clinical trials are still ongoing in India, which, with a population of over 1.3 billion, is the second most populous country in the world after China.
Although Russian authorities gave Sputnik V their regulatory approval under a fast-track procedure in August, tests in Russia to assess its safety and effectiveness are also underway.
“As we look forward to the results of clinical trials in India, we believe that local manufacture of the product is crucial to enable rapid access to patients,” said B. Murali Krishna Reddy, Director of International Marketing at Hetero.
He said the deal rings with a goal promoted by the Indian prime minister to get things done in India.
The number of Covid-19 infections in India stands at 9.27 million, the second highest in the world after the United States, with more than 135,000 deaths in the South Asian country, its economy, like others, has been hit hard by the virus.
Another Indian drug maker, Dr. Reddy’s Laboratories Ltd., is conducting clinical trials with Sputnik V in India and said it expects advanced stage trials to be completed by March 2021.
RDIF spoke about Dr. Reddy’s involvement in the distribution once Sputnik V obtains regulatory approval in India.
Kirill Dmitriev, head of RDIF, said earlier this week that Moscow and its foreign partners have the capacity to manufacture more than a billion doses of Sputnik-V starting next year – enough to vaccinate more than 500 million people – and that it would cost less than $20 per person in international markets.
Friday’s joint statement said Phase III clinical trials of Sputnik-V were also underway in Belarus, the United Arab Emirates, Venezuela and other countries.
RDIF and the National Gamaleya Center said on Tuesday that provisional clinical trial data showed Sputnik-V to be 91.4% effective on day 28 and over 95% effective on day 42.
(Sahar News Monitoring Desk)

Check Also

World leaders express optimism as Biden takes office

World Leaders Express Optimism As Biden Takes Office

BERLIN – Leaders around the world congratulated the US President, Joe Biden, and Vice President, …

Leave a Reply

Your email address will not be published. Required fields are marked *